Effect of mildronate on quality of life of patients with chronic heart failure

Aim. To study quality of life (QL) of patients with chronic heart failure ( CHF) and QL changes resultant from mildronate therapy. Materials and methods. QL was studied in 30 IHD patients with CHF of NYHA c lass II-IV, ejection fraction > 45%; 40 IHD patients without CHF and 30 hea lthy subjects. CHF patients were treated for 30 days with ol al mildronate (250mg 4 times a day). QL was assessed according to the method SF-36 Health Status Survey. Results. QL in CHF patients is much lower than that of the controls. Object ive severity of the disease and subjective satisfaction with life do not al ways coincide. Mildronate in a close 1 g/day per os may be beneficial for L Q of CHF patients. Conclusion. It is thought desirable to include OL in analysis of efficiency of managing patients with CHF. SF-36 is a fool able to follow up changes i n QL of CHF patients within a short-term treatment period.